« Back
Home /
Secukinumab

Secukinumab

Manufacturer	TargetMol
Category	Oncology By Cell Type Hematology Leukemia Reagents & Chemicals Molecules By Organ Bladder Cancer
Type	Molecules
Specific against	other
Amount	5mg
Item no.	TMO-T9930-5mg
Targets	NUMA1
CASRN	875356-43-7
eClass 6.1	32169090
eClass 9.0	32169090
Available
Short Description	Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
Shipping	cool pack
Storage	-20°
Molecular Weight	151 kDa
Pathway	Immunology/Inflammation
Target	IL Receptor

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T9930-5mg-datasheet.pdf

TMO-T9930-5mg-safety-datasheet.pdf